Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price […]
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –– Proceeds will support ongoing comprehensive mid to late-stage clinical development program for ESK-001 in plaque psoriasis, systemic lupus erythematosus (SLE) and uveitis –– Alumis will continue to explore ESK-001’s potential application in other immune-mediated diseases, […]
